Redox imbalance in Parkinson's disease

Biochimica et Biophysica Acta - General Subjects

Volumn 1780, Issue 11, 2008, Pages 1362-1367

  Chinta, Shankar J ^a   Andersen, Julie K ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

Dopaminergic neuron; Glutathione; Iron; Mitochondrial dysfunction; Oxidative stress; Parkinson's disease

Indexed keywords

5 [4 (2 HYDROXY)PIPERAZIN 1 YLMETHYL]QUINOLIN 8 OL; ALPHA SYNUCLEIN; CANNABIS; CARNITINE; CHELATING AGENT; DOPAMINE; ESTROGEN; GINKGO BILOBA EXTRACT; GLUTATHIONE; IRON; NICOTINAMIDE; QUINOLINE DERIVATIVE; RASAGILINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UBIDECARENONE; UNCLASSIFIED DRUG; VK 28;

ANTIOXIDANT ACTIVITY; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; IRON CHELATION; LEWY BODY; MESENCEPHALON; NERVE CELL NECROSIS; ONSET AGE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA;

ANIMALS; ANTIOXIDANTS; DOPAMINE; FREE RADICALS; HUMANS; IRON; OXIDATION-REDUCTION; PARKINSON DISEASE;

EID: 49349106093     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2008.02.005     Document Type: Review

References (92)

1. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
2. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., and Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20 (1973) 415-455
3. Moore D.J., West A.B., Dawson V.L., and Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28 (2005) 57-87
4. Gandhi S., and Wood N.W. Molecular pathogenesis of Parkinson's disease. Hum. Mol. Genet. 14 Spec No. 2 (2005) 2749-2755
5. Lin M.T., and Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443 7113 (Oct 19 2006) 787-795
6. Beal M.F. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann. Neurol. 53 Suppl 3 (2003) S39-S47 discussion S47-38
7. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat Med 10 (2004) S18-S25 Suppl
8. Sies H., and Cadenas E. Oxidative stress: damage to intact cells and organs. Philos. Trans. R. Soc. Lond., B Biol. Sci. 311 (1985) 617-631
9. Calabrese V., Lodi R., Tonon C., D'Agata V., Sapienza M., Scapagnini G., Mangiameli A., Pennisi G., Stella A.M., and Butterfield D.A. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J. Neurol. Sci. 233 (2005) 145-162
10. Albers D.S., and Beal M.F. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J. Neural Transm., Suppl. 59 (2000) 133-154
11. Parker Jr. W.D., Boyson S.J., and Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26 (1989) 719-723
12. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1 (1989) 1269
13. Mann V.M., Cooper J.M., Krige D., Daniel S.E., Schapira A.H., and Marsden C.D. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115 Pt 2 (1992) 333-342
14. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., and Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163 (1989) 1450-1455
15. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58 (2005) 495-505
16. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., and Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39 (2007) 44-84
17. Muller F.L., Liu Y., and Van Remmen H. Complex III releases superoxide to both sides of the inner mitochondrial membrane. J. Biol. Chem. 279 (2004) 49064-49073
18. Pastor N., Weinstein H., Jamison E., and Brenowitz M. A detailed interpretation of OH radical footprints in a TBP-DNA complex reveals the role of dynamics in the mechanism of sequence-specific binding. J. Mol. Biol. 304 (2000) 55-68
19. Iravani M.M., Kashefi K., Mander P., Rose S., and Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110 (2002) 49-58
20. Carr A.C., McCall M.R., and Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 20 (2000) 1716-1723
21. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 Suppl 3 (2003) S26-S36 discussion S36-28
22. Pennathur S., Jackson-Lewis V., Przedborski S., and Heinecke J.W. Mass spectrometric quantification of 3-nitrotyrosine, orthotyrosine, and o, o-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J. Biol. Chem. 274 (1999) 34621-34628
23. Ferrante R.J., Hantraye P., Brouillet E., and Beal M.F. Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Res. 823 (1999) 177-182
24. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., and Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290 (2000) 985-989
25. Clementi E., Brown G.C., Feelisch M., and Moncada S. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 7631-7636
26. Murray J., Taylor S.W., Zhang B., Ghosh S.S., and Capaldi R.A. Oxidative damage to mitochondrial complex I due to peroxynitrite: identification of reactive tyrosines by mass spectrometry. J. Biol. Chem. 278 (2003) 37223-37230
27. Bharath S., and Andersen J.K. Glutathione depletion in a midbrain-derived immortalized dopaminergic cell line results in limited tyrosine nitration of mitochondrial complex I subunits: implications for Parkinson's disease. Antioxid. Redox Signal. 7 7-8 (Jul-Aug 2005) 900-910
28. Chinta S.J., and Andersen J.K. Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. Free Radic. Biol. Med. 41 9 (Nov 1 2006) 1442-1448
29. Jenner P., and Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 (1996) S161-S170
30. Youdim M.B., and Riederer P. Understanding Parkinson's disease. Sci Am 276 (1997) 52-59
31. Scherman D., Desnos C., Darchen F., Pollak P., Javoy-Agid F., and Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann. Neurol. 26 (1989) 551-557
32. Gluck M.R., and Zeevalk G.D. Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases. J. Neurochem. 91 4 (Nov 2004) 788-795
33. Perry T.L., Godin D.V., and Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency?. Neurosci. Lett. 33 (1982) 305-310
34. Perry T.L., and Yong V.W. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67 (1986) 269-274
35. Pearce R.K., Owen A., Daniel S., Jenner P., and Marsden C.D. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transm. 104 (1997) 661-677
36. Jenner P. Presymptomatic detection of Parkinson's disease. J. Neural Transm., Suppl. 40 (1993) 23-36
37. Jenner P., and Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 (1996) S161-S170
38. Jha N., Jurma O., Lalli G., Liu Y., Pettus E.H., Greenamyre J.T., Liu R.M., Forman H.J., and Andersen J.K. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J. Biol. Chem. 275 (2000) 26096-26101
39. Chinta S.J., kumar M.J., Hsu M., Rajagopalan S., Kaur D., Rane A., Nicholls D.G., Choi J., and Andersen J.K. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons results in nigrostriatal degeneration. J. Neurosci. 27 51 (Dec 19 2007) 13997-14006
40. Barker J.E., Heales S.J., Cassidy A., Bolanos J.P., Land J.M., and Clark J.B. Depletion of brain glutathione results in a decrease of glutathione reductase activity; an enzyme susceptible to oxidative damage. Brain Res. 716 (1996) 118-122
41. Kenchappa R.S., Diwakar L., Boyd M.R., and Ravindranath V. Thioltransferase (glutaredoxin) mediates recovery of motor neurons from excitotoxic mitochondrial injury. J. Neurosci. 22 (2002) 8402-8410
42. Berman S.B., and Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73 (1999) 1127-1137
43. Zhang F., and Dryhurst G. Effects of l-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. J. Med. Chem. 37 (1994) 1084-1098
44. Spencer J.P., Jenner P., Daniel S.E., Lees A.J., Marsden D.C., and Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J. Neurochem. 71 (1998) 2112-2122
45. Kumar M.J., and Andersen J.K. Perspectives on MAO-B in aging and neurological disease: where do we go from here?. Mol. Neurobiol. 30 (2004) 77-89
46. Westlund K.N., Denney R.M., Rose R.M., and Abell C.W. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25 (1988) 439-456
47. Berg D., Youdim M.B., and Riederer P. Redox imbalance. Cell Tissue Res. 318 (2004) 201-213
48. Riederer P., Lange K.W., and Youdim M.B. Recent advances in pharmacological therapy of Parkinson's disease. Adv. Neurol. 60 (1993) 626-635
49. Kaur D., and Andersen J. Does cellular iron dysregulation play a causative role in Parkinson's disease?. Ageing Res. Rev. 3 (2004) 327-343
50. Kaur D., and Andersen J. Does cellular iron dysregulation play a causative role in Parkinson's disease?. Ageing Res. Rev. 3 3 (Jul 2004) 327-343
51. Lan J., and Jiang D.H. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural Trans. 104 (1997) 469-481
52. Grunblatt E., Mandel S., Berkuzki T., and Youdim M.B. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord. 14 (1999) 612-618
53. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., and Andersen J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37 (2003) 899-909
54. Lan J., and Jiang D.H. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural Trans. 104 (1997) 469-481
55. Grunblatt E., Mandel S., Berkuzki T., and Youdim M.B. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord. 14 (1999) 612-618
56. Kaur D., Peng J., Chinta S.J., Rajagopalan S., Di Monte D.A., Cherny R.A., and Andersen J.K. Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol. Aging 28 (2007) 907-913
57. Castellani R.J., Siedlak S.L., Perry G., and Smith M.A. Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol. (Berl) 100 (2000) 111-114
58. Schipper H.M., Liberman A., and Stopa E.G. Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Exp. Neurol. 150 (1998) 60-68
59. Braak H., and Braak E. Pathoanatomy of Parkinson's disease. J Neurol 247 Suppl 2 (2000) II3-II10
60. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 (1998) 106-108
61. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
62. Paxinou E., Chen Q., Weisse M., Giasson B.I., Norris E.H., Rueter S.M., Trojanowski J.Q., Lee V.M., and Ischiropoulos H. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21 (2001) 8053-8061
63. Ischiropoulos H., and Beckman J.S. Oxidative stress and nitration in neurodegeneration: cause, effect, or association?. J. Clin. Invest. 111 (2003) 163-169
64. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury Jr. P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294 (2001) 1346-1349
65. Uversky V.N., Li J., and Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein. J. Biol. Chem. 23 276(47) (2001) 44284-44296
66. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., and Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10 (1999) 717-721
67. Uversky V.N., Li J., and Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276 (2001) 44284-44296
68. Duda J.E., Giasson B.I., Gur T.L., Montine T.J., Robertson D., Biaggioni I., Hurtig H.I., Stern M.B., Gollomp S.M., Grossman M., Lee V.M., and Trojanowski J.Q. Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J. Neuropathol. Exp. Neurol. 59 (2000) 830-841
69. Przedborski S., Chen Q., Vila M., Giasson B.I., Djaldatti R., Vukosavic S., Souza J.M., Jackson-Lewis V., Lee V.M., and Ischiropoulos H. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Neurochem. 76 (2001) 637-640
70. Norris E.H., Giasson B.I., Ischiropoulos H., and Lee V.M. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J. Biol. Chem. 278 (2003) 27230-27240
71. Thomas M.P., Chartrand K., Reynolds A., Vitvitsky V., Banerjee R., and Gendelman H.E. Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. J. Neurochem. 100 (2007) 503-519
72. Vila M., and Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat. Med. 10 (2004) S58-S62 Suppl
73. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., and Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10 (1999) 717-721
74. Souza J.M., Daikhin E., Yudkoff M., Raman C.S., and Ischiropoulos H. Factors determining the selectivity of protein tyrosine nitration. Arch. Biochem. Biophys. 371 (1999) 169-178
75. Lee F.J., Liu F., Pristupa Z.B., and Niznik H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. Faseb J. 15 (2001) 916-926
76. Tabrizi S.J., Orth M., Wilkinson J.M., Taanman J.W., Warner T.T., Cooper J.M., and Schapira A.H. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet. 9 (2000) 2683-2689
77. Orth M., Tabrizi S.J., Tomlinson C., Messmer K., Korlipara L.V., Schapira A.H., and Cooper J.M. G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage. Neurochem. Int. 45 (2004) 669-676
78. Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K.E., Staal R., Tieu K., Schmitz Y., Yuan C.A., Rocha M., Jackson-Lewis V., Hersch S., Sulzer D., Przedborski S., Burke R., and Hen R. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 14524-14529
79. Klivenyi P., Siwek D., Gardian G., Yang L., Starkov A., Cleren C., Ferrante R.J., Kowall N.W., Abeliovich A., and Beal M.F. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol. Dis. 21 (2006) 541-548
80. Squier T.C. Oxidative stress and protein aggregation during biological aging. Exp. Gerontol. 36 (2001) 1539-1550
81. Marttila R.J., Lorentz H., and Rinne U.K. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J. Neurol. Sci. 86 (1988) 321-331
82. Fernandez H.H., and Chen J.J. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin. Neuropharmacol. 30 (2007) 150-168
83. Youdim M.B., Fridkin M., and Zheng H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech. Ageing Dev. 126 (2005) 317-326
84. Beal M.F. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J. Bioenerg. Biomembr. 36 (2004) 381-386
85. Singh N., Pillay V., and Choonara Y.E. Advances in the treatment of Parkinson's disease. Prog. Neurobiol. 81 (2007) 29-44
86. Mandel S., Maor G., and Youdim M.B. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J. Mol. Neurosci. 24 (2004) 401-416
87. Schulz J.B., Lindenau J., Seyfried J., and Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. 267 (2000) 4904-4911
88. Chinta S.J., Rajagopalan S., Butterfield D.A., and Andersen J.K. In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: relevance to the role of glutathione in Parkinson's disease. Neurosci. Lett. 402 (2006) 137-141
89. Zeevalk G.D., Manzino L., Sonsalla P.K., and Bernard L.P. Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp. Neurol. 203 (2007) 512-520
90. Bharat S., Cochran B.C., Hsu M., Liu J., Ames B.N., and Andersen J.K. Pre-treatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications for Parkinson's disease therapy. Neurotoxicology 23 (2002) 479-486
91. Karunakaran S., Diwakar L., Saeed U., Agarwal V., Ramakrishnan S., Iyengar S., and Ravindranath V. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid. Faseb J. 21 (2007) 2226-2236
92. Sechi G., Deledda M.G., Bua G., Satta W.M., Deiana G.A., Pes G.M., and Rosati G. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 20 (1996) 1159-1170